Safety of MDCK cell culture-based influenza vaccines

Future Microbiology

Volumn 6, Issue 2, 2011, Pages 143-152

  Gregersen, Jens Peter ^a   Schmitt, Heinz Josef ^a   Trusheim, Heidi ^a   Bröker, Michael ^a  

^a Novartis Vaccines and Diagnostics GmbH   (Germany)

Author keywords

cell culture; influenza; MDCK cells; vaccine safety; vaccines

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ALTEPLASE; BASILIXIMAB; BETA1A INTERFERON; BEVACIZUMAB; CETUXIMAB; DORNASE ALFA; DROTRECOGIN; EFALIZUMAB; ETANERCEPT; IMIGLUCERASE; INFLIXIMAB; INFLUENZA VACCINE; OMALIZUMAB; PALIVIZUMAB; POLIOMYELITIS VACCINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RITUXIMAB; TENECTEPLASE; TRASTUZUMAB; WART VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL CULTURE; CELL STRAIN; CHICKEN; CONTROLLED STUDY; DIPLOIDY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EGG; HUMAN; HUMAN CELL; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA;

ANIMALS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CELL LINE; DOGS; HUMANS; INFLUENZA VACCINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 79952409698     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.161     Document Type: Article

References (27)

1. Devuyst O, Beauvens R, Denef JF, Crabbe J, Abramov M: Subtypes of Madin-Darby canine kidney (MDCK) cells defined by immunocytochemistry: Further evidence for properties of renal collecting ducts. Cell Tissue Res. 277, 231-237 (1994). (Pubitemid 24213093)
2. Liu J, Mani S, Schwartz R, Richman L, Tabor DE: Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 28, 1285-1293 (2010). ■ Basic safety studies for a specific Madin Darby canine kidney (MDCK) cell clone intended for the development of a live attenuated vaccine.
3. Medema JK, Meijer J, Kersten AJ, Horton R: Safety assessment of Madin Darby Canine Kidney Cells as vaccines substrate. Dev. Biol. (Basel) 123, 243-250 (2006). ■ Basic safety studies for adherent MDCK cells used for the development of an inactivated influenza vaccine. (Pubitemid 43207169)
4. Zambon M: Cell culture for surveillance of influenza. Dev. Biol. Stand. 98, 65-71 (1999).
5. Minor PD, Engelhardt OG, Wood JM et al.: Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation. Vaccine 27, 2907-2912 (2009). ■ Describes basic influenza manufacturing issues, such as virus strain derivation and selection, and generation of potency test reagents. Discusses implications of the introduction of cell culture systems.
6. Schild GC, Oxford JS, DeJong JC, Webster RG: Evidence for host-cell selection of influenza virus variants. Nature 303, 706-709 (1983). (Pubitemid 13106735)
7. Oxford JS, Cororan T, Knott R et al.: Serological studies with influenza A (H1N1) viruses cultivated in eggs or in canine kidney cell line (MDCK). Bull. WHO 65, 181-187 (1987). (Pubitemid 17089850)
8. Robertson JS: Clinical influenza virus and the embryonated hen's egg. Med. Virol. 3, 97-106 (1993). ■ References [6-8] describe the mutant selection induced by passages of influenza viruses in embryonated eggs and assess the implications.
9. Katz JM, Webster RG: Efficacy of inactivated influenza A virus (H3N2) vaccine grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160, 191-198 (1989). ■ Animal studies demonstrating higher vaccine protection with influenza virus grown in MDCK cells compared with egg-passage virus. (Pubitemid 19189009)
10. Committee for medical products for human use (CHMP): Concept paper on the need to update the current annex guideline on cell culture inactivated influenza vaccines with respect to the derivation of cell-isolated influenza vaccine viruses. EMEA/CHMP/BWP/481473/2008, EMEA, London, 22 January 2009.
11. European Medicines Agency: Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture. Draft released for consultation. EMA/CHMP/BWP/68803/2010. Available online: See [105].
12. ICH International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use: Harmonized Tripartite Guideline on viral safety evaluations of biotechnology products". ICH Q5A, Geneva 1997. See also CPMP/ICH/295/95: Note for guidance on quality of biotechnology products derived from cell lines of human or animal origin. CPMP/ICH/295/95 (2007). Available online: See [105].
13. Food and Drug Administration: Guidance for Industry. Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. US Food and Drug Administration (2006). Available online: See [106].
14. Trusheim H, Roth B, Wilms R et al.: The MDCK 33016-PF cell line is not only suitable for the production of cell-based influenza vaccine but is also an ideal substrate for influenza virus isolation. Presented at: Options for the Control of Influenza VI, Toronto, Canada, 17-23 June 2007.
15. Gregersen JP: A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 26, 3332-3340 (2008).
16. Onions D, Egan W, Jarrett R, Novicki D, Gregersen JP: Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 38, 544-551 (2010). ■ Detailed description of methods and discussion of results of safety studies for MDCK 33016 PF cells.
17. Liu J, Shi X, Schwartz R, Kemble G: Use of MDCK cells for production of live attenuated influenza vaccines. Vaccine 27, 6460-6463 (2009).
18. Yang H, Zhang L, Galinski M: A probabilistic model for risk assessment of residual host cell DNA in biological products. Vaccine 28, 3308-3311 (2010).
19. Gregersen JP: A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 26, 3297-3304 (2008). ■ Risk assessment algorithm to rate and compare virus safety risks of conventional and cell-derived influenza vaccines for numerous adventitious viruses.
20. Polymenidou M, Trusheim H, Stallmach L et al.: Canine MDCK cell lines are refractory to infection with human and mouse prions. Vaccine 26, 2601-2614 (2008).
21. Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M: A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 27, 6022-6029 (2009).
22. Symczakiewicz-Multanowska A, Groth N, Bugarini R et al.: Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 200, 841-848 (2009).
23. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ: Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: Comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis. 200, 849-857 (2009).
24. Frey S, Vesikari T, Szymczakiewicz-Multanowska A et al.: Clinical efficacy of cell culture-derived and egg-derived inactivated influenza vaccines in healthy adults. Clin. Infect. Dis. 51, 997-1004 (2009). ■ Multicenter clinical efficacy studies comparing conventional and cell-based influenza subunit vaccines.
25. Collin N, de Radiguès X: Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 27, 5184-5186 (2009).
26. Schmitt HJ, Gregersen JP, Trusheim H, Bröker M: [Safety of cell culture-based influenza vaccines]. Med Monatsschr Pharm. 33(1), 4-10 (2010).
27. Rappuoli R. Cell-culture-based vaccine production. Technological Options. The Bridge 36(3), 25-30 (2006).